Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
about
Can tissue-based immune markers be used for studying the natural history of cancer?Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategiesAdvances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaPrevention of progression in monoclonal gammopathy of undetermined significanceNovel strategies to target the ubiquitin proteasome system in multiple myelomaCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Does my patient with a serum monoclonal spike have multiple myeloma?Many multiple myelomas: making more of the molecular mayhemEarly lymphoid lesions: conceptual, diagnostic and clinical challengesMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementMolecular pathogenesis of multiple myeloma: basic and clinical updatesEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesEpidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factorsThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialThe Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service researchMultiple myeloma epidemiology and survival: A unique malignancy.Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data.Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.Predictors of plasma cell disorders among African American patients: a community practice perspective.Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.Polycomb target genes are silenced in multiple myeloma.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidatesGenetic interrogation of circulating multiple myeloma cells at single-cell resolution.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Circulating serum free light chains as predictive markers of AIDS-related lymphoma.Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions.Osteoblastogenesis and tumor growth in myeloma.Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.Implications of heterogeneity in multiple myeloma.The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceTranscriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyIncreased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white womenMedication use and multiple myeloma risk in Los Angeles County.
P2860
Q24605537-FB3337D5-7F7B-4A41-9EB2-9090FE67D218Q24607241-E576CEC8-1906-472E-A1F0-845F681C5F66Q24619589-D69AD097-4E59-4C8E-9803-BAAADEFE5019Q24655581-3D72C9FB-BE85-4EC9-B8EB-92884ECD137BQ26773246-E99852CD-27EA-4B5C-9DD5-785B26B9F216Q26785497-C2477C61-D62E-44BF-B94A-F40CDCE2B7B9Q26821981-7D1E2828-1E64-4BBC-98EA-2771C313959AQ26852892-80CDFF77-1E16-4503-AA6B-E977EF51DAA7Q26996519-AE36EC00-2BAA-4BB5-B58F-BFA8A4B9616FQ26998884-8EE9F48E-289B-4B7F-A030-F6A7538D8787Q27026205-782456BE-2C67-4172-8DA6-C274D3BE1C72Q27026478-C0A2C00B-B61E-4377-9BA5-FCFAD1F728BAQ27685556-05E86407-E6E2-46B8-B8C2-6338E2FD6F65Q28075927-CC937A6F-9197-45D7-8491-8D64DE09E6A1Q28266484-9201B1FA-2733-478D-9CFA-C513CAF698B7Q30239771-B439AD85-CEFE-4ED1-BCB8-66EC5FE7722FQ31141905-23142906-EED6-4006-A42B-42E929FB4C95Q33401759-B1A4B795-D504-4369-9D47-DB3FE5A58040Q33411075-7BA868B6-4A8E-40A9-9383-61A8B045C500Q33412193-1158FC20-F1BD-48E1-9135-180F507D061AQ33588550-DAFB0007-A09E-41B8-9709-43B9CFC72F26Q33590627-46690299-BA60-46A8-80CA-A23E1F2A52FBQ33633898-6427F75A-8D6E-4613-B7A4-8B05F6A35AA1Q33639796-7943834B-6BD2-4B6D-9311-07A8E04BA421Q33664484-D4C394B9-31F4-4D0B-A142-536EFAEDE2A9Q33695919-9F69AB93-8384-4B41-B39A-E269A15A2552Q33710567-D573A8B8-7914-4A9F-AF78-3280AB3DDD8FQ33734421-BECDC7D0-4E9C-42A8-AFEA-3D9963344B2DQ33768466-86662C33-582E-4550-99FA-E155DCACF07FQ33821866-F49F73CC-51A3-4C30-9A5D-3540E27EBA7DQ33846310-B6628D41-9D65-47E6-BF68-203FFC82BABDQ33875675-EFAAA7D4-CEB4-46D9-A3EB-253F604CEBD3Q33914824-F43B1C03-FD8A-4B28-99EC-7FB20573D7D5Q33952861-A7111CE8-7787-4E38-A419-7CCCB733BE45Q33978937-9518DDF9-32AD-4882-9C3B-925469BDBF89Q33997173-35361E82-1150-4A2C-AD6F-B655EC71023FQ34091229-5F36006F-3652-475D-98C0-8A737ED51A75Q34093292-4F5EE7F2-896E-494F-A11C-03FBA6C70EF5Q34122305-31E117E2-4CCB-4000-BD55-DF2405FECC68Q34145450-F657546A-360C-4305-B8BD-C68329582B23
P2860
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@ast
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@en
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@nl
type
label
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@ast
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@en
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@nl
prefLabel
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@ast
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@en
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@nl
P2093
P2860
P50
P3181
P1433
P1476
Monoclonal gammopathy of undet ...... e myeloma: a prospective study
@en
P2093
Dalsu Baris
Jerry A Katzmann
Neil E Caporaso
Raynell J Clark
Robert Hoover
Ruth M Pfeiffer
Shaji Kumar
P2860
P304
P3181
P356
10.1182/BLOOD-2008-12-194241
P407
P577
2009-05-28T00:00:00Z